Therapy Areas: Infectious Diseases
Quanterix Prices USD 60.0m Stock Offering
12 August 2019 - - US-based Quanterix Corp. (NASDAQ: QTRX), a company digitising biomarker analysis with the goal of advancing the science of precision health, has priced an underwritten public offering of 2,376,238 shares of its common stock at a public offering price of USD 25.25 per share, the company said.

All of the shares in the offering will be sold by Quanterix. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately USD 60.0m.

Quanterix has also granted the underwriters a 30-day option to purchase up to an additional 356,435 shares of common stock on the same terms and conditions.

The offering is expected to close on or about August 13, 2019, subject to customary closing conditions.

J.P. Morgan Securities LLC and SVB Leerink LLC are acting as joint book-running managers for the offering. Canaccord Genuity LLC is acting as co-manager for the offering. Perella Weinberg Partners is acting as independent capital markets advisor to Quanterix for the offering.

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health.

The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided by giving researchers the ability to closely examine the continuum from health to disease.

Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.

The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts.
Login
Username:

Password:


Related Headlines